Clinical Trial Update: Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the hepatic pharmacokinetics of Grazoprevir (MK-5172) in participants with chronic hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir (grazoprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C | Phase 1 | Status: WITHDRAWN